Lyell Immunopharma Inc (NASDAQ: LYEL) kicked off on Tuesday, up 15.07% from the previous trading day ,before settling in for the closing price of $2.19. Over the past 52 weeks, LYEL has traded in a range of $1.32-$3.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 428.28% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 8.52%. With a float of $116.53 million, this company’s outstanding shares have now reached $253.96 million.
In an organization with 224 employees, it is important to assess its efficiency.
Lyell Immunopharma Inc (LYEL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lyell Immunopharma Inc is 54.14%, while institutional ownership is 27.92%. The most recent insider transaction that took place on Aug 15 ’23, was worth 132,286. In this transaction Director of this company sold 58,020 shares at a rate of $2.28, taking the stock ownership to the 930,880 shares.
Lyell Immunopharma Inc (LYEL) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$0.2 earnings per share (EPS), higher than consensus estimate (set at -$0.23) by $0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.21 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -7.90% during the next five years compared to -15.28% drop over the previous five years of trading.
Lyell Immunopharma Inc (NASDAQ: LYEL) Trading Performance Indicators
Take a look at Lyell Immunopharma Inc’s (LYEL) current performance indicators. Last quarter, stock had a quick ratio of 16.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4925.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.89 in one year’s time.
Technical Analysis of Lyell Immunopharma Inc (LYEL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.67 million. That was inferior than the volume of 0.97 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 70.40%. Additionally, its Average True Range was 0.19.
During the past 100 days, Lyell Immunopharma Inc’s (LYEL) raw stochastic average was set at 57.49%, which indicates a significant decrease from 85.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 79.41% in the past 14 days, which was lower than the 89.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.17, while its 200-day Moving Average is $2.14. However, in the short run, Lyell Immunopharma Inc’s stock first resistance to watch stands at $2.70. Second resistance stands at $2.88. The third major resistance level sits at $3.13. If the price goes on to break the first support level at $2.27, it is likely to go to the next support level at $2.01. Assuming the price breaks the second support level, the third support level stands at $1.83.
Lyell Immunopharma Inc (NASDAQ: LYEL) Key Stats
The company with the Market Capitalisation of 640.33 million has total of 254,096K Shares Outstanding. Its annual sales at the moment are 130 K in contrast with the sum of -234,630 K annual income. Company’s last quarter sales were recorded 10 K and last quarter income was -52,930 K.
